{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:26:50Z","timestamp":1789129610896,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.repc.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:59:43Z","timestamp":1785995983000},"page":"487-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of sodium-glucose cotransporter 2 inhibitors on blood glucose levels in patients with heart failure with reduced ejection fraction without diabetes"],"prefix":"10.1016","volume":"45","author":[{"given":"Yasser Ahmed","family":"Abd El Hady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd Allah Shahat Ali","family":"Abd Elaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Adly Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2026.04.007_bib0170","first-page":"1161","article-title":"A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial)","volume":"86","author":"Maeng","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.repc.2026.04.007_bib0175","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2026.04.007_bib0180","series-title":"Management of heart failure with reduced ejection fraction in patients with diabetes mellitus and chronic kidney disease. Seminars in Nephrology","year":"2023"},{"key":"10.1016\/j.repc.2026.04.007_bib0185","first-page":"504","article-title":"Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?","volume":"7","author":"Sharma","year":"2022","journal-title":"Basic Transl Sci"},{"key":"10.1016\/j.repc.2026.04.007_bib0190","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40265-018-0901-y","article-title":"The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus","volume":"78","author":"Fattah","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.repc.2026.04.007_bib0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.repc.2026.04.007_bib0200","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2026.04.007_bib0205","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2026.04.007_bib0210","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2026.04.007_bib0215","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2018-02254","article-title":"Attenuation of weight loss through improved antilipolytic effect in adipose tissue via the SGLT2 inhibitor tofogliflozin","volume":"104","author":"Yoshida","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.repc.2026.04.007_bib0220","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.repc.2026.04.007_bib0225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.repc.2026.04.007_bib0230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"17","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.repc.2026.04.007_bib0235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jamacardio.2020.5864","article-title":"Applicability of US food and drug administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in US clinical practice: the get with the guidelines-heart failure (GWTG-HF) Registry","volume":"6","author":"Vaduganathan","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.repc.2026.04.007_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101024","article-title":"Use of sodium\u2013glucose cotransporter 2 inhibitors in hospitalized patients","volume":"3","author":"Unlu","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.repc.2026.04.007_bib0245","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2026.04.007_bib0250","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2026.04.007_bib0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.repc.2026.04.007_bib0260","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2337\/diacare.28.7.1769","article-title":"Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence","volume":"28","author":"Ford","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.repc.2026.04.007_bib0265","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1001\/jama.2020.4501","article-title":"Trends in the prevalence of metabolic syndrome in the United States, 2011\u20132016","volume":"323","author":"Hirode","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2026.04.007_bib0270","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2026.04.007_bib0275","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2026.04.007_bib0280","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.repc.2026.04.007_bib0285","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.repc.2026.04.007_bib0290","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.repc.2026.04.007_bib0295","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.repc.2026.04.007_bib0300","article-title":"Comparative efficacy of dapagliflozin and empagliflozin of a fixed dose in heart failure: a network meta-analysis","volume":"9","author":"Shi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.repc.2026.04.007_bib0305","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2026.04.007_bib0310","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.repc.2026.04.007_bib0315","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001856","article-title":"Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study","volume":"8","author":"Horii","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.repc.2026.04.007_bib0320","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25122757","article-title":"The off-target effects, electrolyte and mineral disorders of SGLT2i","volume":"25","author":"Cianciolo","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.repc.2026.04.007_bib0325","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10157-022-02277-y","article-title":"Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus","volume":"27","author":"Shibata","year":"2023","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.repc.2026.04.007_bib0330","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3904\/kjim.2021.515","article-title":"Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs","volume":"37","author":"Kim","year":"2022","journal-title":"Korean J Intern Med"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255126002386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255126002386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:21:11Z","timestamp":1789125671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255126002386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0870255126002386"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2026.04.007","relation":{},"ISSN":["0870-2551"],"issn-type":[{"value":"0870-2551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of sodium-glucose cotransporter 2 inhibitors on blood glucose levels in patients with heart failure with reduced ejection fraction without diabetes","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Portuguesa de Cardiologia.","name":"copyright","label":"Copyright"}]}}